Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,025 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Béné MC, Zweegman S, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Stoppa AM, van de Donk NWCJ, Wuillème S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Krevvata M, Zhang K, de Boer C, Vara S, Kampfenkel T, Vanquickelberghe V, Vermeulen J, Avet-Loiseau H, Sonneveld P. Moreau P, et al. Among authors: mohty m. Lancet Oncol. 2021 Oct;22(10):1378-1390. doi: 10.1016/S1470-2045(21)00428-9. Epub 2021 Sep 13. Lancet Oncol. 2021. PMID: 34529931 Clinical Trial.
Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen.
Faucher C, Mohty M, Vey N, Gaugler B, Bilger K, Moziconnacci MJ, Stoppa AM, Coso D, Ladaique P, Chabannon C, Reviron D, Maraninchi D, Gastaut JA, Olive D, Blaise D. Faucher C, et al. Among authors: mohty m. Exp Hematol. 2003 Oct;31(10):873-80. doi: 10.1016/s0301-472x(03)00194-2. Exp Hematol. 2003. PMID: 14550802 Free article.
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).
Mohty M, Attal M, Marit G, Bulabois CE, Garban F, Gratecos N, Rio B, Vernant JP, Sotto JJ, Cahn JY, Blaise D, Jouet JP, Facon T, Yakoub-Agha I. Mohty M, et al. Bone Marrow Transplant. 2005 Jan;35(2):165-9. doi: 10.1038/sj.bmt.1704756. Bone Marrow Transplant. 2005. PMID: 15531895
CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Mohty M, Bagattini S, Chabannon C, Faucher C, Bardou VJ, Bilger K, Vey N, Gaugler B, Stoppa AM, Coso D, Ladaique P, Olive D, Viens P, Blaise D. Mohty M, et al. Exp Hematol. 2004 Nov;32(11):1097-102. doi: 10.1016/j.exphem.2004.07.020. Exp Hematol. 2004. PMID: 15539088 Free article. Clinical Trial.
Single-agent thalidomide induces response in T-cell lymphoma.
Damaj G, Bouabdallah R, Vey N, Bilger K, Mohty M, Gastaut JA. Damaj G, et al. Among authors: mohty m. Eur J Haematol. 2005 Feb;74(2):169-71. doi: 10.1111/j.1600-0609.2004.00362.x. Eur J Haematol. 2005. PMID: 15654910
1,025 results